vaccine, hepatitis a


sanofi pasteur


Zuellig Pharma
Concise Prescribing Info
Inactivated hepatitis A vaccine
Avaxim 80U Active immunisation against infection caused by HAV in childn 12 mth-15 yr. Avaxim 160U Prevention of infection caused by HAV in adults & adolescents from 16 yr.
Dosage/Direction for Use
Avaxim 80U 0.5 mL IM inj followed by booster dose preferably 6-36 mth after primary vaccination & may be administered up to 7 yr after primary vaccination. Avaxim 160U 0.5 mL IM inj followed by booster dose preferably 6-12 mth after 1st vaccination & may be administered up to 36 mth after 1st vaccination.
Hypersensitivity to vaccine, neomycin & previous inj. Postpone vaccination in severe acute febrile illness.
Special Precautions
Anaphylactic reaction. Not to be inj intravascularly, intradermally or into buttocks. Not for protection against infection caused by HBV, HCV, hepatitis E virus or other known liver pathogens. Syncope; thrombocytopenia or risk of haemorrhage; phenylketonuria. Immunodeficient patients or on immunosuppressive treatment. Hepatic disease. Not to be used during pregnancy. Lactation.
Adverse Reactions
Cephalalgia; inj site pain; nausea, vomiting, decreased appetite, diarrhoea, abdominal pain; myalgia, arthralgia; fever, asthenia. Avaxim 80U Abnormal crying; malaise; irritability, insomnia; inj site redness, induration or oedema & haematoma; somnolence.
Drug Interactions
Not to be mixed w/ other vaccines. Lowered Ab titres w/ Ig.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BC02 - hepatitis A, inactivated, whole virus ; Belongs to the class of hepatitis viral vaccines.
Avaxim vaccine susp for inj 160 U/0.5 mL
Avaxim vaccine susp for inj 80 U/0.5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in